Bio News
Positive data also reported in myasthenia gravis following stiff-person syndrome results<br>Company targets 2026 FDA filing and hires chief commercial officer
Kyverna Therapeutics’ CAR-T therapy, mip-cel, showed a 100% response rate in patients with myasthenia gravis, strengthening its potential as the first CAR-T therapy for an autoimmune disease. The therapy also produced positive results in a clinical trial for stiff-person syndrome (SPS), and the company plans to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) in the first half of 2026. To support the commercialization of mip-cel, Kyverna recently appointed Nadia Dack, formerly of Omeros, as chief commercial officer (CCO) as it builds out its commercial organization.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
